$The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma$

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma

Relapsed and refractory (R/R) multiple myeloma (MM) constitutes a specific and unmet medical need. Median survival ranges from as little as 6 to 9 months, and responses to treatment are characteristically short. In patients with R/R MM after therapy of bortezomib and/or immunomodulators a bendamusti...

Full description

Bibliographic Details
Main Authors:	S. V. Voloshin, S. S. Bessmeltsev, T. P. Zagoskina, N. V. Medvedeva, K. D. Kaplanov, E. V. Karyagina, A. D. Garifullin, A. Yu. Kuvshinov, L. V. Stelmashenko, K. M. Abdulkadyrov
Format:	Article
Language:	Russian
Published:	ABV-press 2015-10-01
Series:	Onkogematologiâ
Subjects:	multiple myeloma bendamustine bortezomib lenalidomide stem cells transplantation genetic abnormalities
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/149

Similar Items

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

Therapeutic advancements in multiple myeloma
by: Alessandro eGozzetti, et al.
Published: (2014-09-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Advances in multiple myeloma therapy during two past decades
by: Ivan Spicka
Published: (2014-06-01)

Practical Aspects of the Use of Carfilzomib in Multiple Myeloma
by: SV Semochkin, et al.
Published: (2018-12-01)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

New drugs in the therapy of multiple myeloma Novas drogas na terapia do mieloma múltiplo
by: Antonio Palumbo, et al.
Published: (2008-06-01)

Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
by: Susana Aceituno, et al.
Published: (2018-06-01)

The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma
by: Michael A. Firer, et al.
Published: (2021-08-01)

How I manage frontline transplant-eligible multiple myeloma in Italy
by: Vittorio Montefusco, et al.
Published: (2020-09-01)

BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
by: A. S. Kolbin, et al.
Published: (2015-06-01)

LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
by: Patrizia Tosi
Published: (2013-06-01)

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM
by: Friederike Bachmann, et al.
Published: (2021-03-01)

High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
by: Maryam Pourabdollah, et al.
Published: (2016-11-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2014-08-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma
by: Chutima Kunacheewa, et al.
Published: (2021-04-01)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01)

Bendamustine in the Treatment of Relapsed/Refractory Hodgkin’s Lymphoma: Literature Review and Clinical Experience
by: SS Shklyaev, et al.
Published: (2019-03-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-01-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-06-01)

Selective purging of human multiple myeloma cells from peripheral blood mononuclear cells: a preliminary study
by: Lee AJ, et al.
Published: (2019-04-01)

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma
by: Schmidt-Wolf, Ingo G. H., et al.
Published: (2011-01-01)

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
by: Shang-Yi Huang, et al.
Published: (2019-01-01)

New Approaches to Improving Bendamustine Microractor Synthesis
by: A. L. Moldavsky, et al.
Published: (2020-02-01)

Effectiveness of bortezomib and bortezomib-containing programs FOR the treatment of recurrent and resistant multiple myeloma
by: T A Mitina, et al.
Published: (2010-07-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
by: A. S. Kolbin, et al.
Published: (2015-03-01)

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
by: Ana-Alicia López-Iglesias, et al.
Published: (2017-06-01)

Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study
by: Evangelos Terpos, et al.
Published: (2021-04-01)

EXPRESSION OF GENES RESPONSIBLE FOR MULTIDRUG RESISTANCE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
by: Yu. B. Chernykh, et al.
Published: (2016-02-01)

Tratamento do Mieloma Múltiplo recidivado Relapsed Multiple Myeloma treatment
by: Vania T. M. Hungria
Published: (2007-03-01)

A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?
by: Uros Markovic, et al.
Published: (2019-09-01)

Current and Novel Alkylators in Multiple Myeloma
by: Fredrik Schjesvold, et al.
Published: (2021-05-01)